Clinical Trial Update: High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy [Phase 1]

View source ↗

Summary

Phase 1 study completed evaluating high-dose intravitreal ranibizumab for recalcitrant radiation retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: The New York Eye Cancer Center | Conditions: Radiation Retinopathy | Phase 1 | Status: COMPLETED